Vol.45, No.3, 2021, pp.517-520, doi:10.32604/biocell.2021.014621
Mesenchymal stem cell-derived exosome as a nano weapon to target the COVID-19 pandemic
Stem Cell Facility (DBT-Centre of Excellence for Stem Cell Research), All India Institute of Medical Sciences, New Delhi, 110029, India
* Address correspondence to: Sujata Mohanty,
(This article belongs to this Special Issue: Stem Cells, Protein Therapeutics, and Regenerative Medicine)
Received 13 October 2020; Accepted 21 December 2020; Issue published 03 March 2021
In these times of despair when a nano-sized organism, the SARS-CoV-2, has rendered the human race helpless, made the global health status decline, and drowned the world economy, a ray of hope comes from another nano-sized particle, the exosome. The potential of mesenchymal stem cells has already been established in COVID-19; however, cell-based therapy has its risks. We thereby propose cell-free therapy using stem cells-derived exosomes to fight against COVID-19, as they can be a game-changer owing to their immunomodulatory nature, which combats the cytokine storm characterizing this disease, and their practical efficiency, which will realistically aid large access to therapy worldwide.
SARS-CoV-2, Wharton’s Jelly, COVID-19, Cell-free therapy, Exosomes, Immunomodulation
Cite This Article
SHARMA, Y., GUPTA, S., MOHANTY, S. (2021). Mesenchymal stem cell-derived exosome as a nano weapon to target the COVID-19 pandemic. BIOCELL, 45(3), 517–520.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.